Leroux Stéphanie, Biran Valérie, van den Anker John, Gotta Verena, Zhao Wei, Zhang Daolun, Jacqz-Aigrain Evelyne, Pfister Marc
Department of Pediatrics/Neonatology, CIC 1414, CHU Rennes, Rennes, France.
Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, University of Basel, Basel, Switzerland.
Front Pharmacol. 2021 Mar 19;12:634686. doi: 10.3389/fphar.2021.634686. eCollection 2021.
Serum creatinine (SCr) is used as a marker of kidney function to guide dosing of renally eliminated drugs. Serum Cystatin C (S-CysC) has been suggested as a more reliable kidney marker than SCr in adults and children. Purpose of this study was to investigate S-CysC as alternative renal marker to SCr for estimating vancomycin clearance in neonates undergoing intensive care. Vancomycin pharmacokinetics (PK), SCr and S-CysC data were collected in patients undergoing vancomycin treatment in the neonatal intensive care unit of Robert Debré Hospital - Paris. A population PK analysis was performed utilizing routine therapeutic drug monitoring samples. S-CysC and SCr were compared as covariates on vancomycin clearance using stepwise covariate modeling (forward inclusion [ < 0.05] and backward elimination [ < 0.01]). Model performance was evaluated by graphical and statistical criteria. A total of 108 vancomycin concentrations from 66 patients (postmenstrual age [PMA] of 26-46 weeks) were modeled with an allometric one-compartment model. The median (range) values for SCr and S-CysC were 41 (12-153) µmol/l and 1.43 (0.95-2.83) mg/l, respectively. Following stepwise covariate model building, SCr was retained as single marker of kidney function (after accounting for weight and PMA) in the final model. Compared to the final model based on SCr, the alternative model based on S-CysC showed very similar performance (e.g. BIC of 578.3 vs. 576.4) but included one additional covariate: impact of mechanical ventilation on vancomycin clearance, in addition to the effects of size and maturation. ill neonates. However, if using S-CysC for this purpose mechanical ventilation needs to be taken into account.
血清肌酐(SCr)用作肾功能标志物,以指导经肾脏消除药物的给药剂量。血清胱抑素C(S-CysC)已被认为是比SCr更可靠的成人和儿童肾脏标志物。本研究的目的是调查S-CysC作为SCr的替代肾脏标志物,用于估计接受重症监护的新生儿的万古霉素清除率。在巴黎罗伯特·德布雷医院新生儿重症监护病房接受万古霉素治疗的患者中收集万古霉素药代动力学(PK)、SCr和S-CysC数据。利用常规治疗药物监测样本进行群体PK分析。使用逐步协变量建模(向前纳入[<0.05]和向后排除[<0.01])将S-CysC和SCr作为万古霉素清除率的协变量进行比较。通过图形和统计标准评估模型性能。用异速生长单室模型对来自66例患者(月经后年龄[PMA]为26-46周)的108个万古霉素浓度进行建模。SCr和S-CysC的中位数(范围)值分别为41(12-153)µmol/l和1.43(0.95-2.83)mg/l。在逐步协变量模型构建后,SCr被保留为最终模型中肾功能的单一标志物(在考虑体重和PMA之后)。与基于SCr的最终模型相比,基于S-CysC的替代模型表现出非常相似的性能(例如,BIC为578.3对576.4),但包括一个额外的协变量:除了大小和成熟度的影响外,机械通气对万古霉素清除率的影响。然而,对于患病新生儿,如果为此目的使用S-CysC,则需要考虑机械通气。